Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|New England Journal of Medicine|2012Cited by 2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Andrew J. Armstrong, Michael J. Morris et al.|Journal of Clinical Oncology|2016Cited by 1.6k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|The Lancet Oncology|2015Cited by 1.4k
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Brian I. Rini, Eric J. Small|Journal of Clinical Oncology|2008Cited by 907
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate CancerSusan Halabi, Nicholas J. Vogelzang, Eric J. Small et al.|Journal of Clinical Oncology|2003Cited by 678